SREBF1 and fatty liver disease: Peroxisome proliferator-activated receptor α (PPARα) or Kruppel-like factor 15 (KLF15) can also ameliorate hepatic steatosis through inhibition of SREBP-1c activation to reduce the synthesis of fatty acids and triacylglycerols.24